NCT06876714 2026-06-02ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabAlliance for Clinical Trials in OncologyPhase 3 Recruiting1,524 enrolled